BioPorto Diagnostics


DKK609.8m market cap

DKK3.05 last close

BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.

Investment summary

BioPorto has announced a collaboration with the University of Southern Denmark (SDU) to develop a point-of-care (PoC) test for the detection of COVID-19. The test would employ the company’s existing generic Rapid Assay Device (gRAD) platform for POC tests, but would require the development of anti-COVID-19 antibodies, which is being done at SDU.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2018A 26.0 (42.1) (42.5) (24.34) N/A N/A
2019A 26.6 (68.3) (71.1) (39.16) N/A N/A
2020E 35.5 (63.2) (63.3) (33.19) N/A N/A
2021E 135.2 17.3 17.2 8.58 35.5 N/A
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 03/04/2020
Share price graph
Balance sheet
Forecast net debt (DKKm) 37.8
Forecast gearing ratio (%) 112
Price performance
Actual 10.6 5.2 (19.5)
Relative* 21.3 11.2 (21.9)
52-week high/low DKK3.9/DKK1.7
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO